Healthcare venture capitalist firm General Catalyst has led a $168 million series B funding round for biotech company Odyssey Therapeutics.
The company will use the funding to advance its portfolio of precision immunomodulators and oncology medicines. The funding round brings Odyssey's total capital raised to $386 million, according to an Oct. 13 Odyssey news release.
"At General Catalyst, we are committed to investing in companies driving powerful, positive and enduring change, and Odyssey's unyielding commitment to improving the lives of patients by targeting the underlying causes of serious inflammatory diseases and cancer aligns with our mission," General Catalyst Partner Elena Viboch said. "We are confident in Odyssey's vision, proven leadership and ability to pioneer and develop next generation therapeutics through their integrated platform approach, and we look forward to seeing Odyssey work toward achieving their mission of delivering life-enhancing medicines to patients in need."